$3.94
-0.07-1.75%
Ult. Agg.: Oct 26, 4:00 PM
Vanda Pharmaceuticals (VNDA) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Vanda Pharmaceuticals (VNDA) ha pubblicato l'ultima guidance il agosto 5, 2026 per fiscal year 2026. La società ha previsto un fatturato pari a $240M - $290M per il periodo.
Rispetto alle previsioni precedenti, Vanda Pharmaceuticals ha modificato le sue previsioni di fatturato da un intervallo precedente di .
Vanda Pharmaceuticals ha pubblicato {{revenueDirection}} aggiornamenti delle previsioni tra il {{revenuePriorRange}} e il Vanda Pharmaceuticals. 10
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.57 | $-0.66 | $-1.67 | $-0.40 |
| Actual | $-1.04 | $-0.82 | $-2.39 | $-0.38 |
| Surprise | -82.5% | -24.2% | -43.1% | +5.00% |
| Revenue | ||||
| Estimate | $62.1M | $54.7M | $59.1M | $59.2M |
| Actual | $50.5M | $51.7M | $57.2M | $56.3M |
| Surprise | -18.6% | -5.52% | -3.20% | -5.03% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.69 | $-0.48 | $-0.38 | $-0.23 |
| Revenue | ||||
| Consensus | $68.5M | $77.2M | — | — |
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $-1.04 | $-0.57 | -82.5 % |
| Q1 | May 6, 2026 | $-0.82 | $-0.66 | -24.2 % |
| Q4 | Feb 11, 2026 | $-2.39 | $-1.67 | -43.1 % |
| Q3 | Oct 29, 2025 | $-0.38 | $-0.40 | 5.00 % |
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $50.53M | $62.07M | -18.6 % |
| Q1 | May 6, 2026 | $51.72M | $54.74M | -5.52 % |
| Q4 | Feb 11, 2026 | $57.22M | $59.11M | -3.20 % |
| Q3 | Oct 29, 2025 | $56.26M | $59.24M | -5.03 % |